Sedation: EtOH (2.0 g/kg, i.v.), GHB (600 mg/kg, i.v.), L-lactate (MCT inhibitor, 66 mg/kg + 302.5 mg/kg/h), Bicuculline (bic, GABAAR antagonist, 1 mg/kg), SGS742 (SGS, GABABR antagonist, 500, 1000 mg/kg), SCH50911 (SCH, GABABR antagonist, 100, 200 mg/kg) Respiratory depression/fatality and toxicokinetics: GHB (600, 1500 mg/kg, i.v.), GHB/EtOH (steady-state conc. 0.1–0.2% or 0.3–0.4%), GHB/EtOH (steady-state conc. 0.1–0.2% or 0.3–0.4%)/inhibitors or antagonists Oral toxicokinetics:GHB (1.5 g/kg, i.g.), EtOH (2.5 g/kg, i.g.) This evidence concerns the gene SLC16A1 and Respiratory insufficiency due to muscle weakness.